Phil Hyu Lee

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2361797/publications.pdf

Version: 2024-02-01

295 papers	10,232 citations	47409 49 h-index	60403 85 g-index
304 all docs	304 docs citations	304 times ranked	12641 citing authors

#	Article	IF	Citations
1	Circulating micro-RNAs Differentially Expressed in Korean Alzheimerâ€™s Patients With Brain AÎ² Accumulation Activate Amyloidogenesis. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2023, 78, 292-303.	1.7	2
2	Premorbid Educational Attainment and Long-Term Motor Prognosis in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, 129-136.	1.5	3
3	White matter connectivity networks predict levodopa-induced dyskinesia in Parkinsonâ€™s disease. Journal of Neurology, 2022, 269, 2948-2960.	1.8	3
4	Mapping brain structural differences and neuroreceptor correlates in Parkinsonâ€™s disease visual hallucinations. Nature Communications, 2022, 13, 519.	5.8	15
5	Association Between White Matter Connectivity and Early Dementia in Patients With Parkinson Disease. Neurology, 2022, 98, .	1.5	8
6	Interrelation of striatal dopamine, brain metabolism and cognition in dementia with Lewy bodies. Brain, 2022, 145, 4448-4458.	3.7	9
7	Associations between white matter hyperintensities, striatal dopamine loss, and cognition in drug-naÃ¯ve Parkinson's disease. Parkinsonism and Related Disorders, 2022, 97, 1-7.	1.1	7
8	Effects of Alzheimer and Lewy Body Disease Pathologies on Brain Metabolism. Annals of Neurology, 2022, 91, 853-863.	2.8	7
9	Association of Î²-Amyloid and Basal Forebrain With Cortical Thickness and Cognition in Alzheimer and Lewy Body Disease Spectra. Neurology, 2022, 98, .	1.5	10
10	Effects of Alzheimerâ€™s genetic risk scores and CSF biomarkers in de novo Parkinsonâ€™s Disease. Npj Parkinson's Disease, 2022, 8, 57.	2.5	2
11	Gut microbiota-derived metabolite trimethylamine N-oxide as a biomarker in early Parkinson's disease. Nutrition, 2021, 83, 111090.	1.1	36
12	The pattern of FP-CIT PET in pure white matter hyperintensitiesâ€“related vascular parkinsonism. Parkinsonism and Related Disorders, 2021, 82, 1-6.	1.1	2
13	Microstructural Connectivity is More Related to Cognition than Conventional MRI in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2021, 11, 239-249.	1.5	2
14	Inosine 5'â€Monophosphate to Raise Serum Uric Acid Level in Multiple System Atrophy (IMPROVEâ€MSA) Tj ETQq0 0 0 rgBT /Overlock	2.3	6
15	Relationship between Hearing Loss and Dementia Differs According to the Underlying Mechanism.		

#	Article	IF	Citations
19	Donepezil for mild cognitive impairment in Parkinsonâ€™s disease. Scientific Reports, 2021, 11, 4734.	1.6	10
20	Effect of Alzheimerâ€™s Disease and Lewy Body Disease on Metabolic Changes. Journal of Alzheimer's Disease, 2021, 79, 1471-1487.	1.2	2
21	Temporalis Muscle Thickness as an Indicator of Sarcopenia Is Associated With Long-term Motor Outcomes in Parkinsonâ€™s Disease. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 2242-2248.	1.7	5
22	Perivascular Spaces in the Basal Ganglia and Long-term Motor Prognosis in Newly Diagnosed Parkinson Disease. Neurology, 2021, 96, e2121-e2131.	1.5	32
23	Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinsonâ€™s disease. Brain, 2021, 144, 1127-1137.	3.7	30
24	Structural connectivity networks in Alzheimerâ€™s disease and Lewy body disease. Brain and Behavior, 2021, 11, e02112.	1.0	4
25	Different patterns of Î²-amyloid deposition in patients with Alzheimer's disease according to the presence of mild parkinsonism. Neurobiology of Aging, 2021, 101, 199-206.	1.5	2
26	Predicting the longitudinal changes of levodopa dose requirements in Parkinsonâ€™s disease using item response theory assessment of realâ€world Unified Parkinson's Disease Rating Scale. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 611-621.	1.3	9
27	Baseline cognitive profile is closely associated with long-term motor prognosis in newly diagnosed Parkinsonâ€™s disease. Journal of Neurology, 2021, 268, 4203-4212.	1.8	8
28	Neuropsychiatric Burden Is a Predictor of Early Freezing and Motor Progression in Drug-NaÃ¯ve Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2021, 11, 1-10.	1.5	9
29	Clinical and Dopamine Depletion Patterns in Hyposmia- and Dysautonomia-Dominant Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2021, 11, 1-11.	1.5	1
30	Implication of metabolic and dopamine transporter PET in dementia with Lewy bodies. Scientific Reports, 2021, 11, 14394.	1.6	7
31	Association of Dipeptidyl Peptidase-4 Inhibitor Use and Amyloid Burden in Patients With Diabetes and AD-Related Cognitive Impairment. Neurology, 2021, 97, e1110-e1122.	1.5	18
32	Glucocerebrosidase Mutations and Motor Reserve in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2021, 11, 1715-1724.	1.5	6
33	Effects of statins on dopamine loss and prognosis in Parkinsonâ€™s disease. Brain, 2021, 144, 3191-3200.	3.7	22
34	Postganglionic Sudomotor Dysfunction and Brain Glucose Hypometabolism in Patients with Multiple System Atrophy. Journal of Parkinson's Disease, 2021, 11, 1247-1256.	1.5	2
35	Diffusion tensor imagingâ€based pontine damage as a degeneration marker in synucleinopathy. Journal of Neuroscience Research, 2021, 99, 2922-2931.	1.3	1
36	Implication of Small Vessel Disease MRI Markers in Alzheimerâ€™s Disease and Lewy Body Disease1. Journal of Alzheimer's Disease, 2021, 83, 545-556.	1.2	3

#	Article	IF	Citations
37	Neural correlates of selfâ€awareness of cognitive deficits in nonâ€demented patients with Parkinson's disease. European Journal of Neurology, 2021, 28, 4022-4030.	1.7	3
38	Effects of baseline serum uric acid and apolipoprotein E4 on longitudinal cognition and cerebral metabolism. Neurobiology of Aging, 2021, 106, 223-231.	1.5	8
39	Apolipoprotein E4, amyloid, and cognition in Alzheimer's and Lewy body disease. Neurobiology of Aging, 2021, 106, 45-54.	1.5	9
40	Memantine exerts neuroprotective effects by modulating Î±-synuclein transmission in a parkinsonian model. Experimental Neurology, 2021, 344, 113810.	2.0	8
41	Phase I Trial of Intra-arterial Administration of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Patients with Multiple System Atrophy. Stem Cells International, 2021, 2021, 1-10.	1.2	5
42	Effects of Alzheimer's disease and Lewy body disease on subcortical atrophy. European Journal of Neurology, 2020, 27, 318-326.	1.7	9
43	Distinguishing between dementia with Lewy bodies and Alzheimer's disease using metabolic patterns. Neurobiology of Aging, 2020, 87, 11-17.	1.5	15
44	Neural Correlates of Cognitive Performance in Alzheimerâ€™s Disease- and Lewy Bodies-Related Cognitive Impairment. Journal of Alzheimer's Disease, 2020, 73, 873-885.	1.2	4
45	Dysautonomia Is Linked to Striatal Dopamine Deficits and Regional Cerebral Perfusion in Early Parkinson Disease. Clinical Nuclear Medicine, 2020, 45, e342-e348.	0.7	10
46	Clinical and Striatal Dopamine Transporter Predictors of Mild Behavioral Impairment in Drug-Naive Parkinson Disease. Clinical Nuclear Medicine, 2020, 45, e463-e468.	0.7	9
47	Mesenchymal stem cells modulate misfolded Î±-synuclein in parkinsonian disorders: A multitarget disease-modifying strategy. Stem Cell Research, 2020, 47, 101908.	0.3	10
48	Factor analysisâ€“derived cognitive profile predicting early dementia conversion in PD. Neurology, 2020, 95, e1650-e1659.	1.5	21
49	The diagnostic potential of multimodal neuroimaging measures in Parkinson's disease and atypical parkinsonism. Brain and Behavior, 2020, 10, e01808.	1.0	9
50	Minimal parkinsonism in the elderly is associated with striatal dopamine loss and pontine structural damage. Parkinsonism and Related Disorders, 2020, 81, 140-143.	1.1	6
51	Rapid drug increase and early onset of levodopa-induced dyskinesia in Parkinsonâ€™s disease. PLoS ONE, 2020, 15, e0237472.	1.1	7
52	Motor Cerebellar Connectivity and Future Development of Freezing of Gait in De Novo Parkinson's Disease. Movement Disorders, 2020, 35, 2240-2249.	2.2	17
53	Effects of APOE4 on Alzheimerâ€™s disease, Lewy body disease, cerebral amyloid deposition and cognitive dysfunction. Alzheimer's and Dementia, 2020, 16, e037300.	0.4	0
54	Gender-specific effect of urate on white matter integrity in Parkinson's disease. Parkinsonism and Related Disorders, 2020, 75, 41-47.	1.1	7

#	Article	IF	Citations
55	Clinical and striatal dopamine transporter predictors of Î²-amyloid in dementia with Lewy bodies. Neurology, 2020, 94, e1344-e1352.	1.5	17
56	Urate is closely linked to white matter integrity in multiple system atrophy. Annals of Clinical and Translational Neurology, 2020, 7, 1029-1039.	1.7	4
57	Feasibility and Efficacy of Intra-Arterial Administration of Embryonic Stem Cell Derived-Mesenchymal Stem Cells in Animal Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 76, 1281-1296.	1.2	15
58	Patterns of striatal dopamine depletion in early Parkinson disease. Neurology, 2020, 95, e280-e290.	1.5	25
59	<scp>Laterâ€Onset</scp> Multiple System Atrophy: A Multicenter Asian Study. Movement Disorders, 2020, 35, 1692-1693.	2.2	13
60	White matter hyperintensities and risk of levodopaâ€induced dyskinesia in Parkinsonâ€™s disease. Annals of Clinical and Translational Neurology, 2020, 7, 229-238.	1.7	16
61	Identifying the Functional Brain Network of Motor Reserve in Early Parkinson's Disease. Movement Disorders, 2020, 35, 577-586.	2.2	36
62	Cognitive anosognosia is associated with frontal dysfunction and lower depression in Parkinsonâ€™s disease. European Journal of Neurology, 2020, 27, 951-958.	1.7	10
63	Dopaminergic Depletion, Î²â€Amyloid Burden, and Cognition in Lewy Body Disease. Annals of Neurology, 2020, 87, 739-750.	2.8	27
64	Patterns of olfactory functional networks in Parkinson's disease dementia and Alzheimer's dementia. Neurobiology of Aging, 2020, 89, 63-70.	1.5	24
65	Sexâ€dependent association of urate on the patterns of striatal dopamine depletion in Parkinsonâ€™s disease. European Journal of Neurology, 2020, 27, 773-778.	1.7	9
66	Intracellular delivery of Parkin rescues neurons from accumulation of damaged mitochondria and pathological Î±-synuclein. Science Advances, 2020, 6, eaba1193.	4.7	41
67	Impaired functional connectivity of sensorimotor network predicts recovery in drug-induced parkinsonism. Parkinsonism and Related Disorders, 2020, 74, 16-21.	1.1	5
68	Changes in plasma arylsulfatase A level as a compensatory biomarker of early Parkinsonâ€™s disease. Scientific Reports, 2020, 10, 5567.	1.6	7
69	Initial motor reserve and long-term prognosis in Parkinson's disease. Neurobiology of Aging, 2020, 92, 1-6.	1.5	15
70	Association between Olfactory Deficit and Motor and Cognitive Function in Parkinsonâ€™s Disease. Journal of Movement Disorders, 2020, 13, 133-141.	0.7	22
71	Emerging Concepts of Motor Reserve in Parkinsonâ€™s Disease. Journal of Movement Disorders, 2020, 13, 171-184.	0.7	30
72	Subtypes of Sleep Disturbance in Parkinson's Disease Based on the Cross-Culturally Validated Korean		

#	Article	IF	Citations
73	Validation of the Korean Version of the Questionnaire for Impulsive-Compulsive Disorders in		

#	Article	IF	Citations
91	Beneficial effect of estrogen on nigrostriatal dopaminergic neurons in drug-naÃ¯ve postmenopausal Parkinsonâ€™s disease. Scientific Reports, 2019, 9, 10531.	1.6	35
92	Cerebellar connectivity in Parkinson's disease with levodopaâ€induced dyskinesia. Annals of Clinical and Translational Neurology, 2019, 6, 2251-2260.	1.7	15
93	Frontal atrophy as a marker for dementia conversion in Parkinson's disease with mild cognitive impairment. Human Brain Mapping, 2019, 40, 3784-3794.	1.9	41
94	Olfactory anosognosia is a predictor of cognitive decline and dementia conversion in Parkinsonâ€™s disease. Journal of Neurology, 2019, 266, 1601-1610.	1.8	17
95	Low-dose pioglitazone can ameliorate learning and memory impairment in a mouse model of dementia by increasing LRP1 expression in the hippocampus. Scientific Reports, 2019, 9, 4414.	1.6	55
96	Distinct FP-CIT PET patterns of Alzheimerâ€™s disease with parkinsonism and dementia with Lewy bodies. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1652-1660.	3.3	11
97	Mild cognitive impairment reverters have a favorable cognitive prognosis and cortical integrity in Parkinson's disease. Neurobiology of Aging, 2019, 78, 168-177.	1.5	16
98	Effects of Lewy body disease and Alzheimer disease on brain atrophy and cognitive dysfunction. Neurology, 2019, 92, e2015-e2026.	1.5	28
99	Dysautonomia is associated with structural and functional alterations in Parkinson disease. Neurology, 2019, 92, e1456-e1467.	1.5	21
100	Levodopa-induced dyskinesia is closely linked to progression of frontal dysfunction in PD. Neurology, 2019, 92, e1468-e1478.	1.5	16
101	Does the Side Onset of Parkinsonâ€™s Disease Influence the Time to Develop Levodopa-Induced Dyskinesia?. Journal of Parkinson's Disease, 2019, 9, 241-247.	1.5	9
102	P4â€572: NEURAL CORRELATES OF COGNITIVE PERFORMANCE IN ALZHEIMER'S DISEASE AND LEWY BODY DISEASE SPECTRA. Alzheimer's and Dementia, 2019, 15, P1538.	0.4	0
103	P4â€571: DISTINCT FPâ€CIT PET PATTERNS OF ALZHEIMER'S DISEASE WITH PARKINSONISM AND DEMENTIA WITH LEWY BODIES. Alzheimer's and Dementia, 2019, 15, P1538.	0.4	0
104	Enrichment of Exosome-Like Extracellular Vesicles from Plasma Suitable for Clinical Vesicular miRNA Biomarker Research. Journal of Clinical Medicine, 2019, 8, 1995.	1.0	32
105	Focal Task-Specific Lower Limb Dystonia Only When Walking Stairs: Is It a New Disease Entity?. Frontiers in Neurology, 2019, 10, 1081.	1.1	4
106	Detrimental effect of type 2 diabetes mellitus in a large case series of Parkinson's disease. Parkinsonism and Related Disorders, 2019, 64, 54-59.	1.1	20
107	Clinical relevance of amnestic versus nonâ€amnestic mild cognitive impairment subtyping in Parkinson's disease. European Journal of Neurology, 2019, 26, 766-773.	1.7	25
108	Gastrectomy and nigrostriatal dopaminergic depletion in de novo Parkinson's disease. Movement Disorders, 2019, 34, 299-301.	2.2	1

#	Article	IF	Citations
109	Heterogeneous Patterns of Striatal Dopamine Loss in Patients with Young- versus Old-Onset Parkinsonâ€™s Disease: Impact on Clinical Features. Journal of Movement Disorders, 2019, 12, 113-119.	0.7	26
110	The Influence of Body Mass Index at Diagnosis on Cognitive Decline in Parkinson's Disease. Journal of		

#	Article	IF	Citations
127	The role of 18F-FP-CIT PET in differentiation of progressive supranuclear palsy and frontotemporal dementia in the early stage. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1585-1595.	3.3	20
128	Feasibility and Efficacy of Intra-Arterial Administration of Mesenchymal Stem Cells in an Animal Model of Double Toxin-Induced Multiple System Atrophy. Stem Cells Translational Medicine, 2017, 6, 1424-1433.	1.6	16
129	Early-onset mild cognitive impairment in Parkinsonâ€™s disease: Altered corticopetal cholinergic network. Scientific Reports, 2017, 7, 2381.	1.6	15
130	Volumetric analysis of the cerebellum in patients with progressive supranuclear palsy. European Journal of Neurology, 2017, 24, 212-218.	1.7	4
131	Lack of association between LRRK2 G2385R and cognitive dysfunction in Korean patients with Parkinsonâ€™s disease. Journal of Clinical Neuroscience, 2017, 36, 108-113.	0.8	16
132	Dementia-Predicting Cognitive Risk Score and Its Correlation with Cortical Thickness in Parkinson Disease. Dementia and Geriatric Cognitive Disorders, 2017, 44, 203-212.	0.7	16
133	Microstructural white matter alterations in patients with drug induced parkinsonism. Human Brain Mapping, 2017, 38, 6043-6052.	1.9	4
134	Does smoking impact dopamine neuronal loss in de novo Parkinson disease?. Annals of Neurology, 2017, 82, 850-854.	2.8	15
135	Subcortical shape analysis of progressive mild cognitive impairment in Parkinson's disease. Movement Disorders, 2017, 32, 1447-1456.	2.2	34
136	Sleep Disturbance May Alter White Matter and Resting State Functional Connectivities in Parkinsonâ€™s Disease. Sleep, 2017, 40, .	0.6	15
137	Rapid eye movement sleep behaviour disorder and striatal dopamine depletion in patients with Parkinson's disease. European Journal of Neurology, 2017, 24, 1314-1319.	1.7	26
138	The Cleavage Effect of Mesenchymal Stem Cell and Its Derived Matrix Metalloproteinase-2 on Extracellular Î±-Synuclein Aggregates in Parkinsonian Models. Stem Cells Translational Medicine, 2017, 6, 949-961.	1.6	47
139	Mesenchymal Stem Cells Stabilize Axonal Transports for Autophagic Clearance of Î±-Synuclein in Parkinsonian Models. Stem Cells, 2017, 35, 1934-1947.	1.4	30
140	MicroRNA Biomarkers in Neurodegenerative Diseases and Emerging Nano-Sensors Technology. Journal of Movement Disorders, 2017, 10, 18-28.	0.7	23
141	Patients and Their Caregiversâ€™ Burdens for Parkinsonâ€™s Disease in Korea. Journal of Movement Disorders, 2017, 10, 109-115.	0.7	13
142	Familiar Hyperekplexia, a Potential Cause of Cautious Gait: A New Korean Case and a Systematic Review of Phenotypes. Journal of Movement Disorders, 2017, 10, 53-58.	0.7	14
143	Validation of the Korean Version of the Scale for Outcomes in Parkinsonâ€™s Disease-Autonomic. Journal of Movement Disorders, 2017, 10, 29-34.	0.7	32
144	The KMDS-NATION Study: Korean Movement Disorders Society Multicenter Assessment of Non-Motor Symptoms and Quality of Life in Parkinson's Disease NATION Study Group. Journal of Clinical		

#	Article	IF	Citations
145	Persistent Drug-Induced Parkinsonism in Patients with Normal Dopamine Transporter Imaging. PLoS ONE, 2016, 11, e0157410.	1.1	23
146	Striatal Dopamine Depletion Patterns and Early Non-Motor Burden in Parkinsons Disease. PLoS ONE, 2016, 11, e0161316.	1.1	11
147	Does serum uric acid act as a modulator of cerebrospinal fluid Alzheimer's disease biomarker related cognitive decline?. European Journal of Neurology, 2016, 23, 948-957.	1.7	37
148	Cognitive and Neuroanatomical Correlates in Early Versus Late Onset Parkinsonâ€™s Disease Dementia. Journal of Alzheimer's Disease, 2016, 55, 485-495.	1.2	6
149	P2-225: Dopaminergic Depletion in Anterior Caudate and Putamen Causes Cognitive Impairment in Parkinson's Disease. , 2016, 12, P708-P708.		0
150	P3â€180: Effect of Vitamin B12 on Cognition. Alzheimer's and Dementia, 2016, 12, P889.	0.4	0
151	Effect of olfactory impairment and white matter hyperintensities on cognition in Parkinson's disease. Parkinsonism and Related Disorders, 2016, 24, 95-99.	1.1	17
152	Optic nerve integrity as a visuospatial cognitive predictor in Parkinsonâ€™s disease. Parkinsonism and Related Disorders, 2016, 31, 41-45.	1.1	7
153	Correlation of 3D FLAIR and Dopamine Transporter Imaging in Patients With Parkinsonism. American Journal of Roentgenology, 2016, 207, 1089-1094.	1.0	20
154	Mesenchymal stem cells enhance Î±-synuclein clearance via M2 microglia polarization in experimental and human parkinsonian disorder. Acta Neuropathologica, 2016, 132, 685-701.	3.9	83
155	A prognostic factor in focal hand dystonia: typist's cramp cases and literature review. Journal of the Neurological Sciences, 2016, 371, 85-87.	0.3	6
156	P4-121: Neuroprotective Effect of Serum Uric Acid on Alzheimerâ€™s Disease is Mediated by Brain Metabolism Change. , 2016, 12, P1059-P1059.		0
157	Posterior Ventricular Enlargement to Differentiate Dementia with Lewy Bodies from Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 52, 1237-1243.	1.2	6
158	Mesenchymal Stem Cells Inhibit Transmission of Î±-Synuclein by Modulating Clathrin-Mediated Endocytosis in a Parkinsonian Model. Cell Reports, 2016, 14, 835-849.	2.9	66
159	Apathy and striatal dopamine defects in non-demented patients with Parkinson's disease. Parkinsonism and Related Disorders, 2016, 23, 62-65.	1.1	22
160	Different Functional and Microstructural Changes Depending on Duration of Mild Cognitive Impairment in Parkinson Disease. American Journal of Neuroradiology, 2016, 37, 897-903.	1.2	23
161	Association of body mass index and the depletion of nigrostriatal dopamine in Parkinson's disease. Neurobiology of Aging, 2016, 38, 197-204.	1.5	36
162	Weight Change Is a Characteristic Non-Motor Symptom in Drug-NaÃ¯ve Parkinsonâ€™s Disease Patients with Non-Tremor Dominant Subtype: A Nation-Wide Observational Study. PLoS ONE, 2016, 11, e0162254.	1.1	10

#	Article	IF	Citations
163	Clinical Heterogeneity of Atypical Pantothenate Kinase-Associated Neurodegeneration in Koreans. Journal of Movement Disorders, 2016, 9, 20-27.	0.7	21
164	The MMSE and MoCA for Screening Cognitive Impairment in Less Educated Patients with Parkinsonâ€™s Disease. Journal of Movement Disorders, 2016, 9, 152-159.	0.7	41
165	Mesenchymal Stem Cells Increase Hippocampal Neurogenesis and Neuronal Differentiation by Enhancing the Wnt Signaling Pathway in an Alzheimer's Disease Model. Cell Transplantation, 2015, 24, 1097-1109.	1.2	133
166	P3-098: Serum uric acid, cerebrospinal fluid marker of Alzheimer's disease and cognition. , 2015, 11, P657-P658.		0
167	Mesenchymal stem cells stabilize the bloodâ€“brain barrier through regulation of astrocytes. Stem Cell Research and Therapy, 2015, 6, 187.	2.4	54
168	Comparison of regional brain atrophy and cognitive impairment between pure akinesia with gait freezing and Richardson's syndrome. Frontiers in Aging Neuroscience, 2015, 7, 180.	1.7	19
169	Patterns of Neuropsychological Profile and Cortical Thinning in Parkinsonâ€™s Disease with Punding. PLoS ONE, 2015, 10, e0134468.	1.1	20
170	Neuropsychiatric Symptoms in Parkinsonâ€™s Disease Dementia Are Associated with Increased Caregiver Burden. Journal of Movement Disorders, 2015, 8, 26-32.	0.7	36
171	Olfactory performance and resting state functional connectivity in nonâ€demented drug naÃ¯ve patients with Parkinson's disease. Human Brain Mapping, 2015, 36, 1716-1727.	1.9	23
172	Topography of cortical thinning associated with white matter hyperintensities in Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 372-377.	1.1	10
173	Cerebral Microbleeds in Patients with Dementia with Lewy Bodies and Parkinson Disease Dementia. American Journal of Neuroradiology, 2015, 36, 1642-1647.	1.2	28
174	Nigrostriatal dopamine-independent resting-state functional networks in Parkinson's disease. NeuroImage, 2015, 119, 296-304.	2.1	29
175	Effects of Mesenchymal Stem Cell Treatment on the Expression of Matrix Metalloproteinases and Angiogenesis during Ischemic Stroke Recovery. PLoS ONE, 2015, 10, e0144218.	1.1	43
176	Apathy and Olfactory Dysfunction in Early Parkinsonâ€™s Disease. Journal of Movement Disorders, 2015, 8, 21-25.	0.7	24
177	Current Status of Huntingtonâ€™s Disease in Korea: A Nationwide Survey and National Registry Analysis. Journal of Movement Disorders, 2015, 8, 14-20.	0.7	22
178	Gender Differences in Age-Related Striatal Dopamine Depletion in Parkinsonâ€™s Disease. Journal of Movement Disorders, 2015, 8, 130-135.	0.7	29
179	Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinsonâ€™s Disease Dementia. Journal of Movement Disorders, 2015, 8, 98-102.	0.7	37
180	Mesenchymal stem cells can modulate longitudinal changes in cortical thickness and its related cognitive decline in patients with multiple system atrophy. Frontiers in Aging Neuroscience, 2014, 6, 118.	1.7	13

#	Article	IF	Citations
181	Clinical and Genetic Aspects in Twelve Korean Patients with Adrenomyeloneuropathy. Yonsei Medical Journal, 2014, 55, 676.	0.9	17
182	Exploratory analysis of neuropsychological and neuroanatomical correlates of progressive mild cognitive impairment in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 7-16.	0.9	119
183	Mesenchymal stem cells enhance autophagy and increase Î²-amyloid clearance in Alzheimer disease models. Autophagy, 2014, 10, 32-44.	4.3	210
184	Antiâ€NMDA Receptor Encephalitis with a Favorable Prognosis Despite Delayed Treatment Due to Longstanding Psychiatric Symptoms. Movement Disorders Clinical Practice, 2014, 1, 386-387.	0.8	0
185	Endothelial dysfunction and hyperhomocysteinemia in Parkinson's disease: Flow-mediated dilation study. Movement Disorders, 2014, 29, 1551-1555.	2.2	19
186	The burden of white matter hyperintensities is a predictor of progressive mild cognitive impairment in patients with <scp>P</scp>arkinson's disease. European Journal of Neurology, 2014, 21, 922.	1.7	55
187	Neural correlates of progressive reduction of bradykinesia in de novo Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 1376-1381.	1.1	35
188	Acid sphingomyelinase modulates the autophagic process by controlling lysosomal biogenesis in Alzheimerâ€™s disease. Journal of Experimental Medicine, 2014, 211, 1551-1570.	4.2	128
189	The Mild Cognitive Impairment Stage of Dementia With Lewy Bodies and Parkinson Disease. Alzheimer Disease and Associated Disorders, 2014, 28, 151-155.	0.6	21
190	Olfactory performance acts as a cognitive reserve in non-demented patients with Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 186-191.	1.1	26
191	Neuroprotective effects of mesenchymal stem cells through autophagy modulation in a parkinsonian model. Neurobiology of Aging, 2014, 35, 1920-1928.	1.5	63
192	Subcortical vascular dementia (SVaD) without hypertension (HTN) may be a unique subtype of vascular dementia (VaD). Archives of Gerontology and Geriatrics, 2014, 58, 231-235.	1.4	3
193	Depression and voice handicap in Parkinson disease. Journal of the Neurological Sciences, 2014, 346, 112-115.	0.3	22
194	Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease. Neurology, 2014, 82, 1597-1604.	1.5	78
195	Cognitive and cortical thinning patterns of subjective cognitive decline in patients with and without Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 999-1003.	1.1	24
196	Dopaminergic modulation of restingâ€state functional connectivity in de novo patients with Parkinson's disease. Human Brain Mapping, 2014, 35, 5431-5441.	1.9	30
197	Subjective cognitive decline predicts future deterioration in cognitively normal patients with Parkinson's disease. Neurobiology of Aging, 2014, 35, 1739-1743.	1.5	44
198	Cerebral microbleeds in patients with Parkinsonâ€™s disease. Journal of Neurology, 2014, 261, 1628-1635.	1.8	51

#	Article	IF	Citations
199	Predictive value of the smell identification test for nigrostriatal dopaminergic depletion in Korean tremor patients. Parkinsonism and Related Disorders, 2013, 19, 1018-1021.	1.1	4
200	Changes in the bloodâ€“brain barrier status closely correlate with the rate of disease progression in patients with multiple system atrophy: A longitudinal study. Parkinsonism and Related Disorders, 2013, 19, 450-452.	1.1	7
201	Thalamic volume and related visual recognition are associated with freezing of gait in non-demented patients with Parkinson's disease. Parkinsonism and Related Disorders, 2013, 19, 1106-1109.	1.1	30
202	Î±-Synuclein pathology is related to postoperative delirium in patients undergoing gastrectomy. Neurology, 2013, 80, 810-813.	1.5	27
203	Effect of APOE genotype on gray matter density in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2013, 19, 138-140.	1.1	1
204	Dental implantsâ€induced taskâ€specific oromandibular dystonia. European Journal of Neurology, 2013, 20, e80.	1.7	6
205	Levodopaâ€induced dyskinesia in a patient who has normal presynaptic dopaminergic neurons. Movement Disorders, 2013, 28, 1152-1153.	2.2	3
206	Translation and Validation of the Korean Version of the 39-Item Parkinson's Disease Questionnaire.		

#	Article	IF	Citations
217	Elevated Homocysteine by Levodopa Is Detrimental to Neurogenesis in Parkinsonian Model. PLoS ONE, 2012, 7, e50496.	1.1	18
218	Validation of the Korean-Version of the Nonmotor Symptoms Scale for Parkinson's Disease. Journal of		

#	Article	IF	Citations
235	A Long-Term Follow-Up Study of Intravenous Autologous Mesenchymal Stem Cell Transplantation in Patients With Ischemic Stroke. Stem Cells, 2010, 28, 1099-1106.	1.4	694
236	A Comparison of LEDD and Motor Scores Following STN-DBS Treatment in Patient with Young Onset vs. Late Onset Parkinson's Disease. Neuromodulation, 2010, 13, 255-260.	0.4	6
237	A comparative analysis of cognitive profiles and white-matter alterations using voxel-based diffusion tensor imaging between patients with Parkinson's disease dementia and dementia with Lewy bodies. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 320-326.	0.9	93
238	Neuroanatomic basis of amnestic MCI differs in patients with and without Parkinson disease. Neurology, 2010, 75, 2009-2016.	1.5	42
239	Enhancing trophic support of mesenchymal stem cells by ex vivo treatment with trophic factors. Journal of the Neurological Sciences, 2010, 298, 28-34.	0.3	33
240	The missing button sign as a tool for detecting proximal internal carotid artery occlusion. Journal of Clinical Neuroscience, 2010, 17, 1506-1509.	0.8	1
241	Formation of parkin aggregates and enhanced PINK1 accumulation during the pathogenesis of Parkinsonâ€™s disease. Biochemical and Biophysical Research Communications, 2010, 393, 824-828.	1.0	23
242	The effect of levodopa treatment on cerebral hemodynamics in patients with Parkinson's disease: Serial transcranial Doppler studies. Parkinsonism and Related Disorders, 2010, 16, 225-227.	1.1	8
243	A Novel PANK2 Mutation in a Patient with Atypical Pantothenate-Kinase-Associated Neurodegeneration		

#	Article	IF	Citations
253	Parkinsonsim due to a Chronic Subdural Hematoma. Journal of Movement Disorders, 2009, 2, 43-44.	0.7	5
254	A Cerebellar Tremor in a Patient with Human Immunodeficiency Virus-1 Associated with Progressive Multifocal Leukoencephalopathy. Journal of Movement Disorders, 2009, 2, 88-90.	0.7	2
255	Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease. Neurogenetics, 2008, 9, 263-269.	0.7	105
256	Movement disorders at a university hospital emergency room. Journal of Neurology, 2008, 255, 745-749.	1.8	10
257	Autologous Mesenchymal Stem Cell Therapy Delays the Progression of Neurological Deficits in Patients With Multiple System Atrophy. Clinical Pharmacology and Therapeutics, 2008, 83, 723-730.	2.3	204
258	Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinsonâ€™s disease. Journal of Neurochemistry, 2008, 107, 141-151.	2.1	171
259	Cortical metabolic changes in the cerebellar variant of multiple system atrophy: A voxel-based FDG-PET study in 41 patients. NeuroImage, 2008, 40, 796-801.	2.1	29
260	Diffusion Tensor Imaging in Patients With Essential Tremor. American Journal of Neuroradiology, 2008, 29, 151-153.	1.2	115
261	Changes in Cerebral Glucose Metabolism in Patients with Parkinson Disease with Dementia After Cholinesterase Inhibitor Therapy. Journal of Nuclear Medicine, 2008, 49, 2006-2011.	2.8	21
262	Mesenchymal Stem Cells for Ischemic Stroke: Changes in Effects after Ex Vivo Culturing. Cell Transplantation, 2008, 17, 1045-1059.	1.2	86
263	Odour identification test and its relation to cardiac 123I-metaiodobenzylguanidine in patients with drug induced parkinsonism. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1250-1252.	0.9	57
264	Subtraction Brain SPECT Imaging in a Patient With Paroxysmal Exercise-Induced Dystonia. Archives of Neurology, 2007, 64, 1652.	4.9	9
265	Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action. European Journal of Neuroscience, 2007, 26, 79-89.	1.2	128
266	A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies. European Journal of Neurology, 2007, 14, 1357-1362.	1.7	122
267	Two cases of spontaneous middle cerebral arterial dissection causing ischemic stroke. Journal of the Neurological Sciences, 2006, 250, 162-166.	0.3	20
268	Parkinsonism with basal ganglia lesions in a patient with uremia: Evidence of vasogenic edema. Parkinsonism and Related Disorders, 2006, 12, 93-96.	1.1	53
269	Effect of Ischemic Neuronal Insults on Amyloid Precursor Protein Processing. Neurochemical Research, 2006, 31, 821-827.	1.6	26
270	The plasma alpha-synuclein levels in patients with Parkinsonâ€™s disease and multiple system atrophy. Journal of Neural Transmission, 2006, 113, 1435-1439.	1.4	216

#	Article	IF	Citations
271	Cardiac123I-MIBG scintigraphy in patients with essential tremor. Movement Disorders, 2006, 21, 1235-1238.	2.2	29
272	Correlation between cardiac123I-MIBG and odor identification in patients with Parkinson's disease and multiple system atrophy. Movement Disorders, 2006, 21, 1975-1977.	2.2	76
273	Parkinsonism as an initial manifestation of dural arteriovenous fistula. European Journal of Neurology, 2005, 12, 403-406.	1.7	52
274	Thalamic infarct presenting with thalamic astasia. European Journal of Neurology, 2005, 12, 317-319.	1.7	27
275	Autologous mesenchymal stem cell transplantation in stroke patients. Annals of Neurology, 2005, 57, 874-882.	2.8	1,050
276	Correlation of midbrain diameter and gait disturbance in patients with idiopathic normal pressure hydrocephalus. Journal of Neurology, 2005, 252, 958-963.	1.8	42
277	Circulating beta amyloid protein is elevated in patients with acute ischemic stroke. Journal of Neural Transmission, 2005, 112, 1371-1379.	1.4	70
278	Pathogenesis of deep white matter medullary infarcts: a diffusion weighted magnetic resonance imaging study. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1659-1663.	0.9	20
279	Mechanisms of Recurrence in Subtypes of Ischemic Stroke. Archives of Neurology, 2005, 62, 1232.	4.9	57
280	Association of the metabolic syndrome with intracranial atherosclerotic stroke. Neurology, 2005, 65, 296-298.	1.5	137
281	Cardiac 123I-MIBG scintigraphy in patients with drug induced parkinsonism. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 77, 372-374.	0.9	43
282	Specific DWI lesion patterns predict prognosis after acute ischaemic stroke within the MCA territory. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1222-1228.	0.9	86
283	Inflammatory markers, rather than conventional risk factors, are different between carotid and MCA atherosclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1128-1134.	0.9	56
284	Repetitive involuntary leg movements in patients with brainstem lesions involving the pontine tegmentum: evidence for a pontine inhibitory region in humans. Parkinsonism and Related Disorders, 2005, 11, 105-110.	1.1	7
285	Pontine atrophy precedes cerebellar degeneration in spinocerebellar ataxia 7: MRI-based volumetric analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1452-1456.	0.9	47
286	Infarct patterns in atherosclerotic middle cerebral artery versus internal carotid artery disease. Neurology, 2004, 62, 1291-1296.	1.5	56
287	Asymmetric freezing of gait in hemiparkinsonism-hemiatrophy. Neurology, 2004, 63, E7.	1.5	7
288	Isolated middle cerebral artery disease: clinical and neuroradiological features depending on the pathogenesis. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 727-732.	0.9	31

#	Article	IF	Citations
289	Basal ganglia hyperperfusion in a patient with systemic lupus erythematosusâ€“related parkinsonism. Neurology, 2004, 63, 395-396.	1.5	24
290	Global aphasia without hemiparesis: lesion analysis and its mechanism in 11 Korean patients. Journal of the Neurological Sciences, 2004, 217, 101-106.	0.3	13
291	The Course of Patients With Lacunar Infarcts and a Parent Arterial Lesion. Archives of Neurology, 2004, 61, 514.	4.9	51
292	MRI features of infarcts with potential cardiac source of embolism in the Yonsei Stroke Registry (YSR), Korea. Yonsei Medical Journal, 2000, 41, 431.	0.9	3
293	Serial Brain SPECT Images in a Case of Sydenham Chorea. Archives of Neurology, 1999, 56, 237.	4.9	62
294	Isolated weakness of the fingers in cortical infarction. Neurology, 1998, 50, 823-824.	1.5	23
295	Uric Acid Enhances Neurogenesis in a Parkinsonian Model by Remodeling Mitochondria. Frontiers in Aging Neuroscience, 0, 14, .	1.7	3